Get started
Author

Bérengère de Moucheron

Observed names: B. De Moucheron, B. de Moucheron, Berengere De Moucheron, Berengere de Moucheron
OpenAlex ID: A5092121997
Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
2023 · Julio C. Chavez, Loretta J. Nastoupil, et al. · Blood · 14
Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study
2024 · Julio C. Chavez, Guilherme Fleury Perini, et al. · Blood · 4
Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2024 · Jean-Marie Michot, Franck Morschhauser, et al. · Blood · 4
PDF
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results
2025 · Julio Chavez, Jason Westin, et al. · Blood · 2
PDF
IBCL-1109: Golcadomide, a CELMoD Agent, With or Without Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Phase 1/2 Results
2025 · Raul Cordoba, Julio Chavez, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
ABCL-1115: Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD) Agent, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Phase 1/2 Results
2025 · Emmanuel Bachy, Jean-Marie Michot, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
148 | Golcadomide ± Rituximab in Patients With Relapsed/refractory Diffuse Large B‐cell Lymphoma: Updated Phase 1/2 Results
2025 · E. Bachy, J. Michot, et al. · Hematological Oncology · 1
PDF
Open‐label Phase 1/2 Study of Cc‐99282, a Cereblon E3 Ligase Modulator (celmod) Agent ± Rituximab, in Patients With Relapsed/refractory (r/r) Non‐hodgkin Lymphoma (nhl)
2023 · J. M. Michot, J. Chavez, et al. · Hematological Oncology · 1
PDF
Beta-Amyloid induces toxic degenerative pathways on human retinal cells with P2X7 cell death receptor activation: Role in Age-Related Macular Degeneration (AMD)
2011 · P. Rat, A. Waks, et al. · Toxicology Letters · 1
P2‐209: Evaluation and modulation of toxic degenerative pathways induced by beta‐amyloid on retinal cells: Role of P2X7 cell death receptor
2011 · Patrice Rat, Anais Wakx, et al. · Alzheimer s & Dementia · 1
PDF
POSTER: ABCL-1115 Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD) Agent, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Phase 1/2 Results
2025 · Emmanuel Bachy, Jean-Marie Michot, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-1109 Golcadomide, a CELMoD Agent, With or Without Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Phase 1/2 Results
2025 · Raul Cordoba, Julio Chavez, et al. · Clinical Lymphoma Myeloma & Leukemia
91 | Bms‐986458, a First‐in‐class, Bifunctional Cereblon‐dependent Ligand‐directed Degrader (ldd) of B‐cell Lymphoma 6 (bcl6) in Patients With R/r Nhl: Initial Ph 1 Results
2025 · F. Morschhauser, D. Qualls, et al. · Hematological Oncology
PDF
441 | GOLCADOMIDE, A CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED PHASE 1/2 RESULTS
2025 · R. Cordoba, J. Chavez, et al. · Hematological Oncology
PDF
Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome
2024 · Soraya Carrancio, Jessica Voetsch, et al. · Blood
Works count: 15
Citation count: 30
H-index: 3
I10-index: 1
Year
Topic
Type